Next-Generation Stem Cells Cleared for Human Trial
By David Cyranoski,
Nature
| 09. 10. 2014
A Japanese patient with a debilitating eye disease is about to become the first person to be treated with induced pluripotent stem cells, which have generated enthusiastic expectations and earned their inventor a Nobel Prize. A health-ministry committee has vetted researchers' safety tests and cleared the team to begin the experimental procedure.
[Update 12 September: eye specialist Yasuo Kurimoto has now performed the procedure on the first patient, a 70-year-old woman. See 'Japanese woman is first recipient of next-generation stem cells'.]
Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, has been using induced pluripotent stem (iPS) cells to prepare a treatment for age-related macular degeneration. Unlike embryonic stem cells, iPS cells are produced from adult cells, so they can be genetically tailored to each recipient. They are capable of becoming any cell type in the body, and have the potential to treat a wide range of diseases. The CDB trial will be the first opportunity for the technology to prove its clinical value.
In age-related macular degeneration, extra blood vessels form...
Related Articles
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...
By Anna Collinson, Maryam Ahmed and Bella McShane, BBC | 03.12.2024
Women who freeze their eggs are being misled by some UK clinics about their chances of having a baby, a fertility charity says.
The Fertility Network was reacting to BBC analysis that found 41% of clinics offering the service privately...
By Isabelle Bartram, Guest Contributor
| 03.13.2024
Note: This article was originally published in February 2024 in issue 268 of the German-language journal Der Gen-ethische Informationsdienst (GID). It is also part of an English-language dossier on Heritable Human Genome Editing published at the same time. Minor edits have been made.
Calls for German embryo research
Pressure on the German Embryo Protection Act is growing. The scientific community is launching a renewed attack on the controversial law and demands access to embryos for so-called high-ranking research objectives. "Germline therapies" are...
By Andrew Joseph, STAT | 02.22.2024
In the years leading up to Russia’s invasion, Ukraine had become a burgeoning hub of clinical trials, particularly in oncology. The war put a hold on the vast majority of those studies.
But as the country marks two years this...